Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 542919 | NSE: ARTEMISMED

Artemis Medicare Services Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 9, 2025, 8:23 pm

Market Cap 3,277 Cr.
Current Price 238
High / Low 350/141
Stock P/E44.2
Book Value 57.9
Dividend Yield0.19 %
ROCE13.6 %
ROE11.4 %
Face Value 1.00
PEG Ratio0.75

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Artemis Medicare Services Ltd

Competitors of Artemis Medicare Services Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
NG Industries Ltd 57.0 Cr. 170 206/1364.70 1242.06 %6.50 %5.63 % 10.0
Global Longlife Hospital and Research Ltd 25.5 Cr. 24.2 46.4/22.1 25.90.00 %2.51 %4.72 % 10.0
Gian Lifecare Ltd 18.1 Cr. 17.5 29.0/12.14.43 19.20.00 %29.2 %24.6 % 10.0
Fortis Malar Hospitals Ltd 118 Cr. 62.7 108/44.0153 15.967.8 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 26.7 Cr. 4.95 9.50/4.320.70 2.670.00 %15.4 %24.1 % 10.0
Industry Average22,314.27 Cr670.2353.4489.393.10%12.34%12.42%9.12

All Competitor Stocks of Artemis Medicare Services Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 142146163182181187201217210217217235227
Expenses 124129144158156163174184179181181193190
Operating Profit 18171924262527333236364237
OPM % 13%12%12%13%14%13%14%15%15%17%16%18%16%
Other Income 1121121222489
Interest 3445556788888
Depreciation 566788991010101111
Profit before tax 1081114141413191619223127
Tax % 36%-57%22%31%23%23%26%27%29%28%24%27%23%
Net Profit 713910111010141214172321
EPS in Rs 0.511.010.650.730.800.780.731.010.851.021.241.641.51

Last Updated: March 3, 2025, 5:32 pm

Below is a detailed analysis of the quarterly data for Artemis Medicare Services Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹227.00 Cr.. The value appears to be declining and may need further review. It has decreased from 235.00 Cr. (Sep 2024) to ₹227.00 Cr., marking a decrease of 8.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹190.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 193.00 Cr. (Sep 2024) to ₹190.00 Cr., marking a decrease of 3.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Sep 2024) to ₹37.00 Cr., marking a decrease of 5.00 Cr..
  • For OPM %, as of Dec 2024, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Sep 2024) to 16.00%, marking a decrease of 2.00%.
  • For Other Income, as of Dec 2024, the value is ₹9.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Sep 2024) to ₹9.00 Cr., marking an increase of ₹1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹8.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 8.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹11.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 11.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 31.00 Cr. (Sep 2024) to ₹27.00 Cr., marking a decrease of 4.00 Cr..
  • For Tax %, as of Dec 2024, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Sep 2024) to 23.00%, marking a decrease of 4.00%.
  • For Net Profit, as of Dec 2024, the value is ₹21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Sep 2024) to ₹21.00 Cr., marking a decrease of 2.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 1.51. The value appears to be declining and may need further review. It has decreased from ₹1.64 (Sep 2024) to 1.51, marking a decrease of ₹0.13.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:15 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 217261368402459503547563402545714845895
Expenses 194234325359406442480501367477620717745
Operating Profit 2327434353606662356894128150
OPM % 10%11%12%11%11%12%12%11%9%12%13%15%17%
Other Income 21354324737723
Interest 15131299911131211193031
Depreciation 991212151820222121293842
Profit before tax 072127323537329395368100
Tax % -0%-0%12%21%16%24%44%36%20%16%25%28%
Net Profit 07192227272120733404974
EPS in Rs 0.020.320.881.031.291.270.981.540.542.462.963.625.41
Dividend Payout % -0%-0%-0%-0%-0%-0%-0%-0%-0%-0%15%12%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)171.43%15.79%22.73%0.00%-22.22%-4.76%-65.00%371.43%21.21%22.50%
Change in YoY Net Profit Growth (%)0.00%-155.64%6.94%-22.73%-22.22%17.46%-60.24%436.43%-350.22%1.29%

Artemis Medicare Services Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:9%
3 Years:28%
TTM:10%
Compounded Profit Growth
10 Years:22%
5 Years:18%
3 Years:98%
TTM:63%
Stock Price CAGR
10 Years:%
5 Years:70%
3 Years:81%
1 Year:57%
Return on Equity
10 Years:10%
5 Years:8%
3 Years:10%
Last Year:11%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:59 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 2121212121210.00131313131414
Reserves 109116135163183210280301308348393438783
Borrowings 11811085689491114108137190268305307
Other Liabilities 39669093124130160159130145207191215
Total Liabilities 2873133313454224525555815896978829481,318
Fixed Assets 237236239249283309381387372476584699718
CWIP 0001274349568164953344
Investments 0000000246121515
Other Assets 50779194112100124137132152192200541
Total Assets 2873133313454224525555815896978829481,318

Below is a detailed analysis of the balance sheet data for Artemis Medicare Services Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹14.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹783.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹438.00 Cr. (Mar 2024) to ₹783.00 Cr., marking an increase of 345.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹307.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹305.00 Cr. (Mar 2024) to ₹307.00 Cr., marking an increase of 2.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹191.00 Cr. (Mar 2024) to ₹215.00 Cr., marking an increase of 24.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹1,318.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹948.00 Cr. (Mar 2024) to ₹1,318.00 Cr., marking an increase of 370.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹718.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹699.00 Cr. (Mar 2024) to ₹718.00 Cr., marking an increase of 19.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹44.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹33.00 Cr. (Mar 2024) to ₹44.00 Cr., marking an increase of 11.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹15.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹541.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹200.00 Cr. (Mar 2024) to ₹541.00 Cr., marking an increase of 341.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹1,318.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹948.00 Cr. (Mar 2024) to ₹1,318.00 Cr., marking an increase of 370.00 Cr..

Notably, the Reserves (₹783.00 Cr.) exceed the Borrowings (307.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +22455320587241562761129108
Cash from Investing Activity +-5-12-10-14-74-67-50-22-34-106-153-89
Cash from Financing Activity +-18-21-35-2419-1014-33134430-27
Net Cash Flow-1117-183-4526-27-8

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-95.00-83.00-42.00-25.00-41.00-31.00-48.00-46.00-102.00-122.00-174.00-177.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days404139494840525048474336
Inventory Days2626262119
Days Payable144237195189187
Cash Conversion Cycle-78-171-129-120-12040525048474336
Working Capital Days-9-70-59-31-44-53-26-28-15-10-29-17
ROCE %6%8%14%15%16%15%14%11%4%10%11%14%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters69.82%69.59%69.27%68.91%68.91%68.03%68.03%68.03%68.03%67.51%67.17%67.17%
FIIs0.00%0.00%0.00%0.00%0.00%0.07%0.09%0.11%0.10%0.16%0.21%0.65%
DIIs1.10%0.91%0.90%1.15%1.37%1.41%1.51%1.96%2.61%3.45%3.60%4.51%
Government7.37%7.34%7.31%7.27%7.27%7.18%7.18%7.18%7.18%7.12%7.09%7.09%
Public21.71%22.17%22.53%22.65%22.43%23.30%23.18%22.72%22.08%21.76%21.93%20.59%
No. of Shareholders12,09815,17714,63717,99518,10019,08220,52922,37519,99319,79526,05427,004

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Bandhan Small Cap Fund421,0790.157.684072025-03-10103359.21%
LIC MF Focused Fund205,2022.833.744072025-03-1050318.18%
LIC MF Healthcare Fund156,1724.582.854072025-03-1038271.5%
LIC MF Small Cap Fund122,70112.244072025-03-1030047.67%
LIC MF Dividend Yield Fund79,3260.951.454072025-03-1019390.42%
LIC MF Value Fund76,3931.271.394072025-03-1018669.78%
Bandhan Midcap Fund70,0160.111.284072025-03-1017102.95%
LIC MF Equity Savings Fund3,8880.450.074072025-03-10855.28%
Motilal Oswal S&P BSE Healthcare ETF4070.060.014072025-03-100%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.0010.0010.00
Basic EPS (Rs.) 3.622.892.404.9014.95
Diluted EPS (Rs.) 3.532.792.294.9014.95
Cash EPS (Rs.) 6.585.154.0520.9131.80
Book Value[Excl.RevalReserv]/Share (Rs.) 28.4625.3722.23243.05236.99
Book Value[Incl.RevalReserv]/Share (Rs.) 33.4730.4027.29243.05236.99
Revenue From Operations / Share (Rs.) 64.6754.9841.91308.51426.82
PBDIT / Share (Rs.) 10.317.555.3929.2649.90
PBIT / Share (Rs.) 7.345.243.7113.0132.81
PBT / Share (Rs.) 5.043.772.815.6923.14
Net Profit / Share (Rs.) 3.622.832.374.6514.70
NP After MI And SOA / Share (Rs.) 3.622.882.404.9014.95
PBDIT Margin (%) 15.9413.7312.869.4811.69
PBIT Margin (%) 11.359.538.864.217.68
PBT Margin (%) 7.796.866.701.845.42
Net Profit Margin (%) 5.595.155.651.503.44
NP After MI And SOA Margin (%) 5.595.235.731.583.50
Return on Networth / Equity (%) 12.9111.4910.872.026.31
Return on Capital Employeed (%) 12.6710.058.603.5710.13
Return On Assets (%) 5.054.264.481.083.37
Long Term Debt / Equity (X) 0.590.630.550.330.20
Total Debt / Equity (X) 0.660.710.620.330.24
Asset Turnover Ratio (%) 0.930.890.830.680.99
Current Ratio (X) 0.970.820.910.920.74
Quick Ratio (X) 0.920.750.820.840.67
Dividend Payout Ratio (NP) (%) 12.440.000.000.000.00
Dividend Payout Ratio (CP) (%) 6.830.000.000.000.00
Earning Retention Ratio (%) 87.560.000.000.000.00
Cash Earning Retention Ratio (%) 93.170.000.000.000.00
Interest Coverage Ratio (X) 4.485.155.963.005.16
Interest Coverage Ratio (Post Tax) (X) 2.572.933.621.232.52
Enterprise Value (Cr.) 2505.471107.95765.31372.04243.97
EV / Net Operating Revenue (X) 2.851.501.380.910.43
EV / EBITDA (X) 17.8910.9410.739.603.69
MarketCap / Net Operating Revenue (X) 2.631.241.100.710.32
Retention Ratios (%) 87.550.000.000.000.00
Price / BV (X) 6.062.722.080.910.58
Price / Net Operating Revenue (X) 2.631.241.100.710.32
EarningsYield 0.020.040.050.020.10

After reviewing the key financial ratios for Artemis Medicare Services Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 3.62. This value is below the healthy minimum of 5. It has increased from 2.89 (Mar 23) to 3.62, marking an increase of 0.73.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 3.53. This value is below the healthy minimum of 5. It has increased from 2.79 (Mar 23) to 3.53, marking an increase of 0.74.
  • For Cash EPS (Rs.), as of Mar 24, the value is 6.58. This value is within the healthy range. It has increased from 5.15 (Mar 23) to 6.58, marking an increase of 1.43.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 28.46. It has increased from 25.37 (Mar 23) to 28.46, marking an increase of 3.09.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 33.47. It has increased from 30.40 (Mar 23) to 33.47, marking an increase of 3.07.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 64.67. It has increased from 54.98 (Mar 23) to 64.67, marking an increase of 9.69.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 10.31. This value is within the healthy range. It has increased from 7.55 (Mar 23) to 10.31, marking an increase of 2.76.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 7.34. This value is within the healthy range. It has increased from 5.24 (Mar 23) to 7.34, marking an increase of 2.10.
  • For PBT / Share (Rs.), as of Mar 24, the value is 5.04. This value is within the healthy range. It has increased from 3.77 (Mar 23) to 5.04, marking an increase of 1.27.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 3.62. This value is within the healthy range. It has increased from 2.83 (Mar 23) to 3.62, marking an increase of 0.79.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 3.62. This value is within the healthy range. It has increased from 2.88 (Mar 23) to 3.62, marking an increase of 0.74.
  • For PBDIT Margin (%), as of Mar 24, the value is 15.94. This value is within the healthy range. It has increased from 13.73 (Mar 23) to 15.94, marking an increase of 2.21.
  • For PBIT Margin (%), as of Mar 24, the value is 11.35. This value is within the healthy range. It has increased from 9.53 (Mar 23) to 11.35, marking an increase of 1.82.
  • For PBT Margin (%), as of Mar 24, the value is 7.79. This value is below the healthy minimum of 10. It has increased from 6.86 (Mar 23) to 7.79, marking an increase of 0.93.
  • For Net Profit Margin (%), as of Mar 24, the value is 5.59. This value is within the healthy range. It has increased from 5.15 (Mar 23) to 5.59, marking an increase of 0.44.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 5.59. This value is below the healthy minimum of 8. It has increased from 5.23 (Mar 23) to 5.59, marking an increase of 0.36.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 12.91. This value is below the healthy minimum of 15. It has increased from 11.49 (Mar 23) to 12.91, marking an increase of 1.42.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 12.67. This value is within the healthy range. It has increased from 10.05 (Mar 23) to 12.67, marking an increase of 2.62.
  • For Return On Assets (%), as of Mar 24, the value is 5.05. This value is within the healthy range. It has increased from 4.26 (Mar 23) to 5.05, marking an increase of 0.79.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.59. This value is within the healthy range. It has decreased from 0.63 (Mar 23) to 0.59, marking a decrease of 0.04.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.66. This value is within the healthy range. It has decreased from 0.71 (Mar 23) to 0.66, marking a decrease of 0.05.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.93. It has increased from 0.89 (Mar 23) to 0.93, marking an increase of 0.04.
  • For Current Ratio (X), as of Mar 24, the value is 0.97. This value is below the healthy minimum of 1.5. It has increased from 0.82 (Mar 23) to 0.97, marking an increase of 0.15.
  • For Quick Ratio (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has increased from 0.75 (Mar 23) to 0.92, marking an increase of 0.17.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 12.44. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 12.44, marking an increase of 12.44.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.83. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 6.83, marking an increase of 6.83.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 87.56. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 87.56, marking an increase of 87.56.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.17. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 93.17, marking an increase of 93.17.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 4.48. This value is within the healthy range. It has decreased from 5.15 (Mar 23) to 4.48, marking a decrease of 0.67.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.57. This value is below the healthy minimum of 3. It has decreased from 2.93 (Mar 23) to 2.57, marking a decrease of 0.36.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 2,505.47. It has increased from 1,107.95 (Mar 23) to 2,505.47, marking an increase of 1,397.52.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.85. This value is within the healthy range. It has increased from 1.50 (Mar 23) to 2.85, marking an increase of 1.35.
  • For EV / EBITDA (X), as of Mar 24, the value is 17.89. This value exceeds the healthy maximum of 15. It has increased from 10.94 (Mar 23) to 17.89, marking an increase of 6.95.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.63. This value is within the healthy range. It has increased from 1.24 (Mar 23) to 2.63, marking an increase of 1.39.
  • For Retention Ratios (%), as of Mar 24, the value is 87.55. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 87.55, marking an increase of 87.55.
  • For Price / BV (X), as of Mar 24, the value is 6.06. This value exceeds the healthy maximum of 3. It has increased from 2.72 (Mar 23) to 6.06, marking an increase of 3.34.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.63. This value is within the healthy range. It has increased from 1.24 (Mar 23) to 2.63, marking an increase of 1.39.
  • For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.02, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Artemis Medicare Services Ltd as of March 12, 2025 is: ₹233.84

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Artemis Medicare Services Ltd is Overvalued by 1.75% compared to the current share price 238.00

Intrinsic Value of Artemis Medicare Services Ltd as of March 12, 2025 is: 370.75

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Artemis Medicare Services Ltd is Undervalued by 55.78% compared to the current share price 238.00

Last 5 Year EPS CAGR: 58.55%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -32.58, which is a positive sign.
  2. The stock has a low average Cash Conversion Cycle of -25.17, which is a positive sign.
  3. The company has higher reserves (289.77 cr) compared to borrowings (153.46 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (517.00 cr) and profit (35.38 cr) over the years.
  1. The stock has a low average ROCE of 11.50%, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Artemis Medicare Services Ltd:
    1. Net Profit Margin: 5.59%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.67% (Industry Average ROCE: 12.34%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 12.91% (Industry Average ROE: 12.42%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 2.57
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.92
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 44.2 (Industry average Stock P/E: 53.44)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.66
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Artemis Medicare Services Ltd. is a Public Limited Listed company incorporated on 18/05/2004 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L85110DL2004PLC126414 and registration number is 126414. Currently Company is involved in the business activities of Hospital activities. Company's Total Operating Revenue is Rs. 845.23 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesPlot No. 14, Delhi Delhi 110075investor@artemishospitals.com
http://www.artemishospitals.com
Management
NamePosition Held
Mr. Onkar KanwarChairman & Non-Exe.Director
Dr.(Mrs.) Devlina ChakravartyManaging Director
Mr. Neeraj KanwarNon Executive Director
Dr. Nirmal Kumar GangulyNon Executive Director
Mrs. Shalini Kanwar ChandNon Executive Director
Dr. Sanjaya BaruIndependent Director
Ms. Deepa Gopalan WadhwaIndependent Director
Mr. Sunil TandonIndependent Director
Mr. Sanjib SenIndependent Director
Dr. Subbaraman NarayanIndependent Director

FAQ

What is the latest intrinsic value of Artemis Medicare Services Ltd?

The latest intrinsic value of Artemis Medicare Services Ltd as on 12 March 2025 is ₹233.84, which is 1.75% lower than the current market price of 238.00, indicating the stock is overvalued by 1.75%. The intrinsic value of Artemis Medicare Services Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹3,277 Cr. and recorded a high/low of ₹350/141 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹783 Cr and total liabilities of ₹1,318 Cr.

What is the Market Cap of Artemis Medicare Services Ltd?

The Market Cap of Artemis Medicare Services Ltd is 3,277 Cr..

What is the current Stock Price of Artemis Medicare Services Ltd as on 12 March 2025?

The current stock price of Artemis Medicare Services Ltd as on 12 March 2025 is ₹238.

What is the High / Low of Artemis Medicare Services Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Artemis Medicare Services Ltd stocks is ₹350/141.

What is the Stock P/E of Artemis Medicare Services Ltd?

The Stock P/E of Artemis Medicare Services Ltd is 44.2.

What is the Book Value of Artemis Medicare Services Ltd?

The Book Value of Artemis Medicare Services Ltd is 57.9.

What is the Dividend Yield of Artemis Medicare Services Ltd?

The Dividend Yield of Artemis Medicare Services Ltd is 0.19 %.

What is the ROCE of Artemis Medicare Services Ltd?

The ROCE of Artemis Medicare Services Ltd is 13.6 %.

What is the ROE of Artemis Medicare Services Ltd?

The ROE of Artemis Medicare Services Ltd is 11.4 %.

What is the Face Value of Artemis Medicare Services Ltd?

The Face Value of Artemis Medicare Services Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Artemis Medicare Services Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE